Evaluating the impact of age on immune checkpoint therapy biomarkers

著者: Rossin Erbe, Zheyu Wang, Sharon Wu, Joanne Xiu, Neeha Zaidi, Jennifer La, David Tuck, Nathanael R. Fillmore, Nicolás A. Giraldo, Michael J. Topper, Stephen B. Baylin, Marc E. Lippman, Claudine Isaacs, Reva Basho, Ilya G. Serebriiskii, Heinz‐Josef Lenz, Igor Astsaturov, John L. Marshall, Josephine A. Taverna, Jerry Lee, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Ashani T. Weeraratna, Hariharan Easwaran, Elana J. Fertig - Cell Reports 2021 被引用: 80

(Cell Reports 36, 109599-1–109599-12.e1–e4; August 24, 2021) In the originally published version of this article, Hariharan Easwaran should have been listed as a corresponding author. The designation is now applied here and with the article online. The production team apologizes for the error. Evaluating the impact of age on immune checkpoint therapy biomarkersErbe et al.Cell ReportsAugust 24, 2021In BriefErbe et al. use multi-omics databases to evaluate biomarkers that are used to predict the response of patients with cancer to ICB in the context of aging. Erbe et al. find that biomarkers associated with ICB response are enriched in tumors from older patients relative to their younger counterparts. Full-Text PDF Open Access